|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
154,660,000 |
Market
Cap: |
156.21(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.429 - $1.75 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Adaptimmune Therapeutics is a biopharmaceutical company focused on developing T-cell therapies for solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. Co. has clinical trials on its ADP-A2M4, ADP-A2M4CD8, each targeting the MAGE-A4 antigen, and ADP-A2AFP SPEAR T-cells targeting the alpha fetoprotein (AFP) cancer antigen in solid tumor types including non-small cell lung cancer, head and neck cancer, ovarian, urothelial, melanoma, and hepatocellular.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
165,799 |
218,930 |
354,372 |
Total Sell Value |
$0 |
$124,385 |
$172,782 |
$411,912 |
Total People Sold |
0 |
4 |
5 |
6 |
Total Sell Transactions |
0 |
16 |
19 |
41 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Orbimed Capital Gp V Llc |
Director |
|
2018-06-06 |
4 |
S |
$13.49 |
$21,584 |
I/I |
(1,600) |
4,901,310 |
|
- |
|
Thompson Peter A |
Director |
|
2018-06-06 |
4 |
S |
$13.49 |
$21,584 |
I/I |
(1,600) |
4,901,310 |
|
- |
|
Orbimed Capital Gp V Llc |
Director |
|
2018-06-04 |
4 |
S |
$13.57 |
$232,047 |
I/I |
(17,100) |
4,902,910 |
|
- |
|
Thompson Peter A |
Director |
|
2018-06-04 |
4 |
S |
$13.57 |
$232,047 |
I/I |
(17,100) |
4,902,910 |
|
- |
|
Orbimed Capital Gp V Llc |
Director |
|
2018-06-01 |
4 |
S |
$13.49 |
$674,500 |
I/I |
(50,000) |
4,920,010 |
|
- |
|
Thompson Peter A |
Director |
|
2018-06-01 |
4 |
S |
$13.49 |
$674,500 |
I/I |
(50,000) |
4,920,010 |
|
- |
|
Orbimed Capital Gp V Llc |
Director |
|
2018-05-30 |
4 |
S |
$13.52 |
$1,635,920 |
I/I |
(121,000) |
4,970,010 |
|
- |
|
Thompson Peter A |
Director |
|
2018-05-30 |
4 |
S |
$13.52 |
$1,635,920 |
I/I |
(121,000) |
4,970,010 |
|
- |
|
Orbimed Capital Gp V Llc |
Director |
|
2018-05-14 |
4 |
S |
$13.50 |
$139,050 |
I/I |
(10,300) |
5,091,010 |
|
- |
|
Thompson Peter A |
Director |
|
2018-05-14 |
4 |
S |
$13.50 |
$139,050 |
I/I |
(10,300) |
5,091,010 |
|
- |
|
Thompson Peter A |
Director |
|
2018-03-29 |
4 |
S |
$11.53 |
$368,764 |
I/I |
(31,983) |
5,101,310 |
|
- |
|
Orbimed Capital Gp V Llc |
Director |
|
2018-03-29 |
4 |
S |
$11.53 |
$368,764 |
I/I |
(31,983) |
5,101,310 |
|
- |
|
Thompson Peter A |
Director |
|
2018-03-27 |
4 |
S |
$11.50 |
$11,684,966 |
I/I |
(1,016,084) |
5,133,293 |
|
- |
|
Orbimed Capital Gp V Llc |
Director |
|
2018-03-27 |
4 |
S |
$11.50 |
$11,684,966 |
I/I |
(1,016,084) |
5,133,293 |
|
- |
|
Baskett Forest |
10% Owner |
|
2018-03-27 |
4 |
B |
$1.92 |
$11,500,200 |
I/I |
6,000,000 |
79,978,672 |
1.5 |
- |
|
Florence Anthony A. Jr. |
10% Owner |
|
2018-03-27 |
4 |
B |
$1.92 |
$11,500,200 |
I/I |
6,000,000 |
79,978,672 |
1.5 |
- |
|
Viswanathan Ravi |
10% Owner |
|
2018-03-27 |
4 |
B |
$1.92 |
$11,500,200 |
I/I |
6,000,000 |
79,978,672 |
1.5 |
- |
|
Kerins Patrick J |
10% Owner |
|
2018-03-27 |
4 |
B |
$1.92 |
$11,500,200 |
I/I |
6,000,000 |
79,978,672 |
1.5 |
- |
|
Barris Peter J |
10% Owner |
|
2018-03-27 |
4 |
B |
$1.92 |
$11,500,200 |
I/I |
6,000,000 |
79,978,672 |
1.5 |
- |
|
Nea 14 Gp, Ltd |
10% Owner |
|
2018-03-27 |
4 |
B |
$1.92 |
$11,500,200 |
D/D |
6,000,000 |
79,978,672 |
2.45 |
- |
|
Mott David M |
Director |
|
2018-03-27 |
4 |
B |
$1.92 |
$11,500,200 |
I/I |
6,000,000 |
79,978,672 |
2.25 |
- |
|
Sandell Scott D |
10% Owner |
|
2018-03-27 |
4 |
B |
$1.92 |
$11,500,200 |
I/I |
6,000,000 |
79,978,672 |
1.5 |
- |
|
Sonsini Peter W. |
10% Owner |
|
2018-03-27 |
4 |
B |
$1.92 |
$11,500,200 |
I/I |
6,000,000 |
79,978,672 |
1.5 |
- |
|
Barrett M James |
10% Owner |
|
2018-03-27 |
4 |
B |
$1.92 |
$11,500,200 |
I/I |
6,000,000 |
79,978,672 |
1.5 |
- |
|
Baskett Forest |
10% Owner |
|
2018-03-26 |
4 |
B |
$1.90 |
$1,087,553 |
I/I |
571,164 |
73,978,672 |
1.5 |
- |
|
234 Records found
|
|
Page 6 of 10 |
|
|